Brief: Oryzon Gets EMA Approval For Phase Ib Study Of Iadademstat In Sickle Cell Disease
25/08/2025 07:08
Aug 25 (Reuters) - Oryzon Genomics SA ORY.MC: RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL TO INITIATE PHASE IB STUDY OF IADADEMSTAT IN SICKLE CELL DISEASE TRIAL'S PRIMARY OBJECTIVES TO BE TO EVALUATE SAFETY AND TOLERABILITY OF IADADEMSTAT, TO ESTABLISH ITS RECOMMENDED PHASE 2 DOSE Source text Further company coverage: ORY.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on ORYZON Genomics SA
See all newsBrief: Oryzon Gets New Patent Grants For Vafidemstat In Four Countries
Brief: Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
Spanish stocks - Factors to watch on Aug 31
Brief: Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application
Spanish stocks - Factors to watch on July 28